Extending multilevel analysis of individual heterogeneity and discriminatory accuracy to time-to-event outcomes: an application of survival MAIHDA to Korean health data
Journal of Epidemiology and Community Health · 2025
DOI: 10.1136/jech-2025-224939 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Epidemiology and Community Health, 2025. Verfasst von Jin-Hwan Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Seoul National University Institute of Health and Environment, Seoul, Korea (the Republic of). Hauptthemen laut MEDLINE: Multilevel Analysis, Health Status Disparities. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Background
Multilevel analysis of individual heterogeneity and discriminatory accuracy (MAIHDA) is a leading quantitative approach for intersectionality-informed health research, but most applications analyse binary or cross-sectional outcomes, ignoring event timing. We applied a multilevel survival (shared frailty) model within the MAIHDA framework to examine intersectional disparities in time-to-diagnosis of hypertension.
Methods
Using 2019 Korean Community Health Survey data (n=228 632), we defined intersectional strata by sex, education, income and residential area. Three survival specifications were implemented: accelerated failure time (AFT), parametric proportional hazards (PHs) and semi-parametric Cox PH models, each with stratum-level random intercepts (shared frailty terms). Between-stratum variance was summarised with the variance partition coefficient (VPC) where estimable and proportional change in variance quantified fixed-effect contributions. Stratum-specific random effects were compared across model types to assess ranking stability.
Results
Between-stratum variance was small overall (AFT VPC: 1.8%), but several strata deviated markedly from the grand mean. Strata with low education and low income were diagnosed earlier than average, while high-education, low-income strata were diagnosed later. Geographic context modified these effects. Time-to-diagnosis patterns often diverged from prevalence patterns. Across models, random effect estimates and ranks were highly correlated (Spearman’s ρ >0.97), though some middle-ranked strata shifted by up to six positions.
Conclusions
Applying a multilevel survival (shared frailty) model within MAIHDA enables examination of when disparities emerge, not just whether they exist. This approach retains MAIHDA’s interpretability while leveraging time-to-event data, offering advantages in settings with incomplete follow-up or irregular observation windows.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Seoul National University Institute of Health and Environment, Seoul, Korea (the Republic of).
- Seoul National University Institute of Health and Environment, Seoul, Korea (the Republic of) lwj221@snu.ac.kr.
- Department of Public Health Science, Seoul National University Graduate School of Public Health, Seoul, Korea (the Republic of).
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, J. H., & Lee, W. (2025). Extending multilevel analysis of individual heterogeneity and discriminatory accuracy to time-to-event outcomes: an application of survival MAIHDA to Korean health data. Journal of Epidemiology and Community Health. https://doi.org/10.1136/jech-2025-224939
Vancouver
Kim JH, Lee W. Extending multilevel analysis of individual heterogeneity and discriminatory accuracy to time-to-event outcomes: an application of survival MAIHDA to Korean health data. Journal of Epidemiology and Community Health. 2025. doi:10.1136/jech-2025-224939
BibTeX
@article{Kim2025,
author = {Kim, Jin-Hwan and Lee, Woojoo},
title = {Extending multilevel analysis of individual heterogeneity and discriminatory accuracy to time-to-event outcomes: an application of survival MAIHDA to Korean health data},
journal = {Journal of Epidemiology and Community Health},
year = {2025},
doi = {10.1136/jech-2025-224939}
}
EUVIMED